InnoTherapy
Unprecedented Surgical Biomaterials with Adhesion Power.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| KRW | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 152 % | 35 % | (14 %) | (15 %) | (27 %) | 257 % | 258 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (443 %) | (502 %) | (529 %) | (762 %) | (1040 %) | (243 %) | (51 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (503 %) | (576 %) | (511 %) | (992 %) | (1614 %) | (380 %) | (79 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 208 % | 281 % | 362 % | 93 % | 35 % |
Source: Company filings or news article
Related Content
InnoTherapy specializes in developing innovative blood technology solutions, particularly in the area of hemostasis, which is the process of stopping bleeding. The company leverages protein-based advancements to create cutting-edge medical products. InnoTherapy serves healthcare providers and medical institutions, primarily operating in the Asian market. The business model includes research and development collaborations, licensing agreements, and strategic partnerships. Revenue is generated through product sales, licensing fees, and collaborative research funding. The company is committed to global marketing and overseas clinical study approvals to expand its market reach.
Keywords: hemostasis, blood technology, protein advancements, healthcare innovation, medical products, R&D collaborations, licensing, strategic partnerships, global marketing, clinical studies.
